116 related articles for article (PubMed ID: 25103124)
21. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction.
Colantonio LD; Deng L; Chen L; Farkouh ME; Monda KL; Harrison DJ; Maya JF; Kilgore ML; Muntner P; Rosenson RS
Cardiovasc Drugs Ther; 2018 Dec; 32(6):601-610. PubMed ID: 30446883
[TBL] [Abstract][Full Text] [Related]
22. Causal inference using mixture models: a word of caution.
Robbins MW; Setodji CM
Med Care; 2014 Sep; 52(9):770-2. PubMed ID: 25119952
[No Abstract] [Full Text] [Related]
23. Knowing the previously unknown: identification of a methodological challenge for pharmacoepidemiology.
Fischer MA
Med Care; 2014 Sep; 52(9):767-9. PubMed ID: 25119951
[No Abstract] [Full Text] [Related]
24. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
25. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
26. Predicting the Overuse of PCSK-9 Inhibitors.
Rodriguez-Gutierrez R; Shah ND; Montori VM
JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456
[No Abstract] [Full Text] [Related]
27. Estimating Generic Drug Use with Electronic Health Records Data from a Health Care Delivery System: Implications for Quality Improvement and Research.
Nimbal V; Segal JB; Romanelli RJ
J Manag Care Spec Pharm; 2016 Oct; 22(10):1143-7. PubMed ID: 27668562
[TBL] [Abstract][Full Text] [Related]
28. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
[TBL] [Abstract][Full Text] [Related]
29. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
[TBL] [Abstract][Full Text] [Related]
30. Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
Straka RJ; Keohane DJ; Liu LZ
Am J Ther; 2017 May; 24(3):e278-e289. PubMed ID: 26099048
[TBL] [Abstract][Full Text] [Related]
31. Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study.
Engelkes M; van Blijderveen JC; Overbeek JA; Kuiper J; Herings RCM; Sturkenboom MCJM; de Jongste JC; Verhamme KMC; Janssens HM
J Asthma; 2018 Oct; 55(10):1086-1094. PubMed ID: 29185812
[TBL] [Abstract][Full Text] [Related]
32. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.
MacKrill K; Petrie KJ
BMJ Open; 2018 Oct; 8(10):e023667. PubMed ID: 30341138
[TBL] [Abstract][Full Text] [Related]
33. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
[TBL] [Abstract][Full Text] [Related]
34. Switching from branded to generic inhaled medications: potential impact on asthma and COPD.
Lavorini F; Ninane V; Haughney J; Bjermer L; Molimard M; Dekhuijzen RP
Expert Opin Drug Deliv; 2013 Dec; 10(12):1597-602. PubMed ID: 24224777
[TBL] [Abstract][Full Text] [Related]
35. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
36. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
Treur M; Heeg B; Möller HJ; Schmeding A; van Hout B
BMC Health Serv Res; 2009 Feb; 9():32. PubMed ID: 19226465
[TBL] [Abstract][Full Text] [Related]
37. Generic statins: effectiveness, affordability, and patient adherence.
Cullen W; Murray P; Harnett A
Ann Intern Med; 2014 Sep; 161(6):447-8. PubMed ID: 25222391
[No Abstract] [Full Text] [Related]
38. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
39. Incorporating tailored interactive patient solutions using interactive voice response technology to improve statin adherence: results of a randomized clinical trial in a managed care setting.
Stacy JN; Schwartz SM; Ershoff D; Shreve MS
Popul Health Manag; 2009 Oct; 12(5):241-54. PubMed ID: 19848566
[TBL] [Abstract][Full Text] [Related]
40. Prevention of Statin Overtreatment and Increased Patient Compliance in High-Cardiovascular-Risk Individuals.
Schade DS; Obenshain SS; Eaton RP
Am J Med; 2019 Oct; 132(10):1123-1125. PubMed ID: 30953634
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
